Compare Cadila Healthcare with Novartis - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CADILA HEALTHCARE vs NOVARTIS - Comparison Results

CADILA HEALTHCARE     Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

NOVARTIS 
   Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CADILA HEALTHCARE NOVARTIS CADILA HEALTHCARE/
NOVARTIS
 
P/E (TTM) x 24.9 2,030.6 1.2% View Chart
P/BV x 4.4 27.0 16.2% View Chart
Dividend Yield % 0.8 1.6 48.3%  

Financials

 CADILA HEALTHCARE   NOVARTIS
EQUITY SHARE DATA
    CADILA HEALTHCARE
Mar-20
NOVARTIS
Mar-19
CADILA HEALTHCARE/
NOVARTIS
5-Yr Chart
Click to enlarge
High Rs352980 35.9%   
Low Rs207600 34.4%   
Sales per share (Unadj.) Rs139.2198.7 70.1%  
Earnings per share (Unadj.) Rs11.821.0 56.1%  
Cash flow per share (Unadj.) Rs18.622.3 83.4%  
Dividends per share (Unadj.) Rs3.5010.00 35.0%  
Dividend yield (eoy) %1.31.3 99.0%  
Book value per share (Unadj.) Rs101.4307.5 33.0%  
Shares outstanding (eoy) m1,023.7424.69 4,146.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.04.0 50.5%   
Avg P/E ratio x23.737.7 63.0%  
P/CF ratio (eoy) x15.035.5 42.4%  
Price / Book Value ratio x2.82.6 107.3%  
Dividend payout %29.847.7 62.4%   
Avg Mkt Cap Rs m286,03319,508 1,466.3%   
No. of employees `00013.40.6 2,307.2%   
Total wages/salary Rs m24,1451,171 2,061.7%   
Avg. sales/employee Rs Th10,632.78,445.4 125.9%   
Avg. wages/employee Rs Th1,801.22,015.7 89.4%   
Avg. net profit/employee Rs Th898.5891.0 100.8%   
INCOME DATA
Net Sales Rs m142,5314,907 2,904.8%  
Other income Rs m1,139783 145.5%   
Total revenues Rs m143,6705,689 2,525.2%   
Gross profit Rs m24,198123 19,705.2%  
Depreciation Rs m6,96532 21,902.5%   
Interest Rs m3,41816 21,496.9%   
Profit before tax Rs m14,954858 1,743.5%   
Minority Interest Rs m2880-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3,198340 940.6%   
Profit after tax Rs m12,044518 2,326.4%  
Gross profit margin %17.02.5 678.4%  
Effective tax rate %21.439.6 53.9%   
Net profit margin %8.510.6 80.1%  
BALANCE SHEET DATA
Current assets Rs m87,1548,055 1,082.1%   
Current liabilities Rs m82,6941,850 4,469.7%   
Net working cap to sales %3.1126.4 2.5%  
Current ratio x1.14.4 24.2%  
Inventory Days Days7145 158.7%  
Debtors Days Days9434 276.6%  
Net fixed assets Rs m133,236150 88,942.6%   
Share capital Rs m1,024123 829.8%   
"Free" reserves Rs m102,7337,469 1,375.6%   
Net worth Rs m103,7577,592 1,366.7%   
Long term debt Rs m32,1460-   
Total assets Rs m236,8669,824 2,411.0%  
Interest coverage x5.454.9 9.8%   
Debt to equity ratio x0.30-  
Sales to assets ratio x0.60.5 120.5%   
Return on assets %6.55.4 120.2%  
Return on equity %11.66.8 170.2%  
Return on capital %13.711.5 119.3%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m52,75258 91,583.3%   
Fx outflow Rs m14,5041,326 1,093.6%   
Net fx Rs m38,248-1,269 -3,014.7%   
CASH FLOW
From Operations Rs m25,054-1,943 -1,289.6%  
From Investments Rs m-10,1232,742 -369.1%  
From Financial Activity Rs m-10,942-298 3,669.3%  
Net Cashflow Rs m3,989501 795.7%  

Share Holding

Indian Promoters % 74.8 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 8.3 2.0 415.0%  
FIIs % 5.9 1.6 368.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 11.0 21.5 51.2%  
Shareholders   44,069 41,647 105.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CADILA HEALTHCARE With:   ORCHID PHARMA  CIPLA  ASTRAZENECA PHARMA  AUROBINDO PHARMA  STERLING BIOTECH  

Compare CADILA HEALTHCARE With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

A Time Correction in the Nifty(Momentum Moves)

The week belonged to the bulls after bears ended the party in February. March started with gains for the bulls but historically, March has been a bears' month.

Related Views on News

CADILA HEALTHCARE Announces Quarterly Results (3QFY21); Net Profit Up 40.6% (Quarterly Result Update)

Feb 10, 2021 | Updated on Feb 10, 2021

For the quarter ended December 2020, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (up 40.6% YoY). Sales on the other hand came in at Rs 38 bn (up 4.3% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

CADILA HEALTHCARE 2019-20 Annual Report Analysis (Annual Result Update)

Oct 26, 2020 | Updated on Oct 26, 2020

Here's an analysis of the annual report of CADILA HEALTHCARE for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of CADILA HEALTHCARE. Also includes updates on the valuation of CADILA HEALTHCARE.

CADILA HEALTHCARE Announces Quarterly Results (1QFY21); Net Profit Up 49.3% (Quarterly Result Update)

Aug 21, 2020 | Updated on Aug 21, 2020

For the quarter ended June 2020, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (up 49.3% YoY). Sales on the other hand came in at Rs 36 bn (up 4.1% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

NOVARTIS Announces Quarterly Results (3QFY20); Net Profit Down 39.9% (Quarterly Result Update)

Feb 17, 2020 | Updated on Feb 17, 2020

For the quarter ended December 2019, NOVARTIS has posted a net profit of Rs 77 m (down 39.9% YoY). Sales on the other hand came in at Rs 1 bn (down 13.4% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

CADILA HEALTHCARE Announces Quarterly Results (2QFY20); Net Profit Down 79.3% (Quarterly Result Update)

Nov 15, 2019 | Updated on Nov 15, 2019

For the quarter ended September 2019, CADILA HEALTHCARE has posted a net profit of Rs 829 m (down 79.3% YoY). Sales on the other hand came in at Rs 34 bn (up 13.7% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

More Views on News

Most Popular

It's the Beginning of a New Bull Phase in Smallcaps(Profit Hunter)

Feb 24, 2021

Last time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.

Make Rs 5,000 Per Day Trading the Market(Fast Profits Daily)

Feb 25, 2021

In this video, I'll show you how to get started on the path to daily trading profits.

The Hidden Tesla in My Great Indian Wealth Project(Profit Hunter)

Feb 23, 2021

An Indian company founded three decades ago in a garage caught my attention...

Gold 65,000 and Silver 84,000 in 2022

Feb 26, 2021

In this episode of the Investor Hour, India's #1 trader, Vijay Bhambwani, talks to us about the stock market, his new targets for gold and silver, the best long-term investment opportunity, and a lot more.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

CADILA HEALTHCARE SHARE PRICE


Mar 5, 2021 (Close)

TRACK CADILA HEALTHCARE

  • Track your investment in CADILA HEALTHCARE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON CADILA HEALTHCARE

CADILA HEALTHCARE - LUPIN COMPARISON

COMPARE CADILA HEALTHCARE WITH

MARKET STATS